A Dual PTPN2/PTPN1 Active-Site Inhibitor Promotes Antitumor Immunity

Article navigation

Research Watch| December 12 2023

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (12): 2500.

Abstract

ABBV-CLS-484, an active-site inhibitor of PTPN2/PTPN1, elicits immune-dependent antitumor efficacy.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.